West Conshohocken, PA, 16 September 2025: SERB Pharmaceuticals (“SERB”), a global specialty pharmaceutical company focused on rare diseases and medical emergencies, today announced the successful completion of its acquisition of Y-mAbs Therapeutics, Inc. (“Y-mAbs”), a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer. “We are excited […]

SERB Pharmaceuticals and Y-mAbs Therapeutics, Inc. have entered into a definitive merger agreement under which SERB will acquire Y-mAbs, including its lead commercial oncology asset, DANYELZA®.

– Phase 3 trial achieved primary endpoint, quickly and safely restoring platelet function in ticagrelor-treated patients undergoing urgent surgery or experiencing major bleeding  – Results presented today in Late-Breaking Clinical Trial Session at the American College of Cardiology Annual Scientific Session  SFJ Pharmaceuticals (SFJ) and SERB Pharmaceuticals (SERB) announced today the final results of the pivotal […]